IRADIMED reports record Q4 revenue $17.5M (+17.4%); initiates quarterly dividend; FY24 guidance $72-74M

IRADIMED CORP

2023-FY EPS reported $1.35 revenue$65,562,296

Record Q4 2023 revenue $17.5M (+17.4% YoY); GAAP diluted EPS $0.36 vs $0.29, non-GAAP $0.39 vs $0.32.
Full-year 2023 revenue $65.6M (+23% YoY); GAAP EPS $1.35, non-GAAP EPS $1.48; operating income $20.0M (+28.2%).
Guidance Q1 2024: rev $17.0-17.3M, GAAP EPS $0.29-0.31, non-GAAP $0.33-0.35. FY2024: rev $72-74M, GAAP EPS $1.37-1.47, non-GAAP $1.52-1.62.
CEO announces initiation of a quarterly dividend in 2024 (amount and record date not specified in release).
Operating cash flow for FY2023 $13.5M vs $10.0M; expects ~$13M capex for new Orlando facility in 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

IRADIMED CORP reported the fourth quarter and full year ended December 31, 2023 results: revenue $17.5 million for the fourth quarter and $65.6 million for the full year of 2023, net income $4.5 million, or $0.36 per diluted share, EPS $0.36. Guidance initiated.

Period: the fourth quarter and full year ended December 31, 2023
Revenue: $17.5 million for the fourth quarter and $65.6 million for the full year of 2023
Net income: $4.5 million, or $0.36 per diluted share
EPS: $0.36
Guidance: initiated
Result: reported results

Exact text from the filing

IRADIMED CORPORATION Announces Fourth Quarter of 2023 and Full Year of 2023 Financial Results ● Reports record revenue of $17.5 million for the fourth quarter and $65.6 million for the full year of 2023.

View on SEC.gov

Browse all earnings releases →

IRADIMED CORP filing history →

Source: SEC EDGAR

accession 0001558370-24-000877

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.